NCT03490760 - "Durvalumab and Booster Radiation in Metastatic Adenocarcinoma of the Pancreas" | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

July 9, 2020

Study Completion Date

July 9, 2020

Conditions

Adenocarcinoma of the Pancreas

Interventions

DRUG

Durvalumab

Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks

RADIATION

Radiation Therapy

24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.

Trial Locations (1)

Miami Cancer Institute at Baptist Health, Inc., Miami